Pyxis Oncology (PYXS) vs Vanda Pharmaceuticals (VNDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vanda Pharmaceuticals (VNDA) has outperformed Pyxis Oncology (PYXS) over the past year, losing 17.0% versus a loss of 31.6%. Over five years, VNDA leads with a -75.4% price change compared with -83.1% for PYXS. Vanda Pharmaceuticals is the larger company by market cap ($275.4 million vs $243.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PYXS | VNDA |
|---|---|---|
| Share price | $2.04 | $4.56 |
| Market cap | $243.09M | $275.41M |
| 1-day change | +2.26% | +0.55% |
| YTD return | +73.04% | -48.64% |
| 1-year return | -31.62% | -17.03% |
| 5-year return | -83.09% | -75.39% |
| Forward P/E | — | 22.78 |
| EPS (TTM) | $-1.40 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.55 | $9.94 |
| 52-week low | $1.03 | $4.27 |
| Distance from 52-week high | -63.33% | -54.18% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +326.04% | +157.96% |
| Average volume | 1.26M | 974.13K |
| Shares outstanding | 119.46M | 60.46M |
| Employees | 56 | 533 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VNDA has outperformed PYXS by 14.6 percentage points over the past year.
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
PYXS vs VNDA FAQ
Which is bigger, Pyxis Oncology or Vanda Pharmaceuticals?
Vanda Pharmaceuticals (VNDA) is larger, with a market capitalization of $275.41M compared with $243.09M for Pyxis Oncology (PYXS).
Which stock has performed better over the past year, PYXS or VNDA?
VNDA returned -17.03% over the past 12 months, compared with -31.62% for PYXS (price return, excluding dividends). Past performance does not predict future results.
Are Pyxis Oncology and Vanda Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.